Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 29;12:649492. doi: 10.3389/fphys.2021.649492

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Yamaguchi, Kitami, Wu, He, Wang, Wang and Komatsu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Treatment with PARP inhibitor Olaparib causes cleft palate in mice. (A) Schematic representation of the in vivo dosing of Olaparib (50 mg/kg) and tissue harvesting schedule. (B) Phenotypic penetrance of cleft palate at E16.5 following i.p. injection of Olaparib (50 mg/kg) into pregnant C57BL/6 mice. (C) Gross morphology of cleft palate (asterisk, upper panels) and skeletal analysis (middle panels) in embryos harvested from C57BL/6 pregnant females injected with Olaparib. The lower panel shows the high-magnification images of the area highlighted in the yellow boxes in the middle panel. mx, maxilla; pmx, premaxilla; ppmx, palatal process of maxilla; ppp, palatal process of palatine.